کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
7279803 | 1473900 | 2017 | 32 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease
ترجمه فارسی عنوان
اثرات آنتیبادیهای خنثی کننده اینترلوکین -6 بر روی علائم خلق و خوی افسرده و انجونیا در بیماران مبتلا به آرتریت روماتوئید و بیماری کولمنت مولتی کانتیک
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TNFαIFN-αPDMAMCDSF-36MTXIL-1b - IL-1BsIL-6R - SIL-6RRheumatoid arthritis (RA) - آرتریت روماتوئید (RA)Rheumatoid arthritis - آرتریتروماتوئیدMajor depressive disorder (MDD) - اختلال افسردگی عمده (MDD)Depression - افسردگیAnhedonia - انهدونیاinterferon alpha - اینترفرون آلفاtumor necrosis factor alpha - تومور نکروز عامل آلفاCytokine - سیتوکینSiltuximab - سیلوکسیمابMethotrexate - متوتروکساتSoluble interleukin-6 receptor - گیرنده اینترلوکین 6 قابل حل است
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
چکیده انگلیسی
Cytokines, including interleukin-6 (IL-6), modulate neuronal plasticity and stress coping. Depressive symptoms and major depressive disorder (MDD) have been associated with changes in cytokines and their signaling. The current study examined the effect of IL-6 monoclonal antibody administration on depressive symptoms in patients with rheumatoid arthritis (RA) or multicentric Castleman's disease (MCD). The data were obtained from two phase 2, double-blind, placebo-controlled trials designed to test the efficacy of sirukumab in RA (NÂ =Â 176) or of siltuximab in MCD (NÂ =Â 65), and were analyzed post hoc to investigate the effects of these IL-6 antibodies on depressive symptoms. The SF-36 questionnaire items on depressed-mood and anhedonia were combined as the measure for depressive symptoms. The study participants were grouped by the presence/absence of prevalent depressed mood and anhedonia (PDMA, meaning either depressed mood or anhedonia was present at least 'most of the time' and the other at least 'some of the time' for four weeks) at baseline; 26.1% of the RA sample and 15.4% of the MCD sample met criteria for PDMA at baseline. Compared with placebo, sirukumab and siltuximab produced significantly greater improvements on depressive symptoms. To account for an effect on mood due to changes in RA or MCD, the analysis was (1) adjusted for symptom severities using DAS28-CRP for RA and MCDOS for MCD alone or together with bodily pain and physical functioning, and (2) performed within RA and MCD non-responders. Improvement in depressive symptoms remained significant in the treated group for both drugs. The significance over placebo was also observed in the siltuximab study. The improvement in depressive symptoms by sirukumab correlated positively with the baseline soluble IL-6 receptor levels. The data together suggest that the IL-6 antibodies improve depressive symptoms in patients with RA and MCD. Further studies are needed to elucidate to what extents the IL-6 antibodies improve depressive symptoms through improving primary disease dependent and independent mechanisms, especially in RA patients, and the brain mechanisms underlying depressive symptom improvements.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Brain, Behavior, and Immunity - Volume 66, November 2017, Pages 156-164
Journal: Brain, Behavior, and Immunity - Volume 66, November 2017, Pages 156-164
نویسندگان
Yu Sun, Dai Wang, Giacomo Salvadore, Benjamin Hsu, Mark Curran, Corey Casper, Jessica Vermeulen, Justine M. Kent, Jaskaran Singh, Wayne C. Drevets, Gayle M. Wittenberg, Guang Chen,